A. Undas et al., Simvastatin depresses blood clotting by inhibiting activation of prothrombin, factor V, and factor XIII and by enhancing factor Va inactivation, CIRCULATION, 103(18), 2001, pp. 2248-2253
Citations number
28
Categorie Soggetti
Cardiovascular & Respiratory Systems","Cardiovascular & Hematology Research
Background-The mechanism of the antithrombotic action of statins is unclear
. The aim of this study was to evaluate the effects of simvastatin on the c
oagulation process at sites of microvascular injury.
Methods and Results-Tissue factor-initiated coagulation was assessed in blo
od samples collected every 30 seconds from bleeding-time wounds of 17 patie
nts who had advanced coronary artery disease and total cholesterol levels o
f 224.6+/-11.8 mg/dL (mean+/-SEM). Quantitative Western blotting for time c
ourses of fibrinogen depletion and activation of prothrombin, factor V, and
factor XIII was performed before and after 3 months of simvastatin treatme
nt (20 mg/d). Simvastatin induced reductions in total cholesterol (23%) and
LDL-cholesterol (36%), which were accompanied by significant decreases in
the rates of prothrombin activation (16.2+/-2.1%; P=0.004), formation of al
pha -thrombin B-chain (27.4+/-1.8%: P=0.001), generation of factor Va heavy
chain (29.7+/-3.1%; P=0.007) and factor Va light chain (18.9+/-1.2%; P=0.0
2), factor XIII activation (19.8+/-1.3%; P=0.001), and fibrinogen conversio
n to fibrin (72.2+/-3%; P=0.002). Posttreatment fibrinopeptides A and B con
centrations, determined by using high-performance liquid chromatography, we
re reduced within the last 30 seconds of bleeding. The 30-kDa fragment of t
he factor Va heavy chain (residues 307 to 506), produced by activated prote
in C, and the 97-kDa fragment of the factor Va heavy chain (residues 1 to 6
43) were released more rapidly after simvastatin treatment. The antithrombo
tic actions of simvastatin showed no relationship to its cholesterol-loweri
ng action.
Conclusions-Simvastatin treatment depresses blood clotting, which leads to
reduced rates of prothrombin activation, factor Va generation, fibrinogen c
leavage, factor XIII activation, and an increased rate of factor Va inactiv
ation. These effects are not related to cholesterol reduction.